Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Taiyen Biotech CoTPE:1737 -0.31%84 Cyclically Adjusted PS Ratio is 1.67 as of Jul. 31, 2026, which is 12% below its 10-year median of 1.90. GuruFocus rates TPE:1737 with a GF Score™ of 84/100 and a GF Value™ of NT$31.83 (Fairly Valued). The stock has 2 warning signs investors should review. Among 1,451 Consumer Packaged Goods companies, Taiyen Biotech Co ranks worse than 73.74% on this metric.
The historical rank and industry rank for Taiyen Biotech Co's Cyclically Adjusted PS Ratio or its related term are showing as below:
TPE:1737'
s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 1.63 Med: 1.9 Max: 2.37
Current: 1.67
During the past years, Taiyen Biotech Co's highest Cyclically Adjusted PS Ratio was 2.37. The lowest was 1.63. And the median was 1.90.
TPE:1737's Cyclically Adjusted PS Ratio is ranked worse than 73.74% of 1451
companies
in the Consumer Packaged Goods industry
Industry Median: 0.76
vs TPE:1737: 1.67
The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.
Taiyen Biotech Co's adjusted revenue per share data for the three months ended in Mar. 2026 was NT$3.948. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is NT$19.24 for the trailing ten years ended in Mar. 2026.
Shiller PE for Stocks: The True Measure of Stock Valuation
Taiyen Biotech Co (TPE:1737) Cyclically Adjusted PS Ratio Explanation
Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.
If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.
Taiyen Biotech Co Cyclically Adjusted PS Ratio Related Terms
Taiyen Biotech Co Cyclically Adjusted PS Ratio Historical Data
* Premium members only.
The historical data trend for Taiyen Biotech Co's Cyclically Adjusted PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Taiyen Biotech Co Cyclically Adjusted PS Ratio Chart
TPE:1737 vs PG, CL, KVUE: Cyclically Adjusted PS Ratio Comparison
For the Household & Personal Products subindustry, Taiyen Biotech Co's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Taiyen Biotech Co Cyclically Adjusted PS Ratio vs Consumer Packaged Goods Industry
For the Consumer Packaged Goods industry and Consumer Defensive sector, Taiyen Biotech Co's Cyclically Adjusted PS Ratio distribution charts can be found below:
* The bar in red indicates where Taiyen Biotech Co's Cyclically Adjusted PS Ratio falls into.
Taiyen Biotech Co Cyclically Adjusted PS Ratio Calculation
Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.
The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.
Taiyen Biotech Co's Cyclically Adjusted PS Ratio for today is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.
What does a Cyclically Adjusted PS Ratio of 1.67 mean?
Taiyen Biotech Co (TPE:1737) has a Cyclically Adjusted PS Ratio of 1.67 as of Jul. 31, 2026. Cyclically Adjusted PS Ratio is the ratio of share price to a company's inflation-adjusted revenue per share over a 10-year period. View historical data on Taiyen Biotech Co and its competitors. This is 12% below median its historical median of 1.90. Over the past decade, Taiyen Biotech Co's Cyclically Adjusted PS Ratio has ranged from 1.63 to 2.37. According to the industry distribution chart, Taiyen Biotech Co ranks #1070 out of 1451 companies in the Consumer Packaged Goods industry, placing it in the top 73.7%.
Is Taiyen Biotech Co's Cyclically Adjusted PS Ratio too high?
Taiyen Biotech Co's current Cyclically Adjusted PS Ratio of 1.67 is 12% below median its 10-year median of 1.90. Over the past 10 years, this metric has ranged from a low of 1.63 to a high of 2.37. The Consumer Packaged Goods industry median Cyclically Adjusted PS Ratio is 0.76. Taiyen Biotech Co's value of 1.67 is 119.7% above this industry median. Based on the distribution chart, Taiyen Biotech Co ranks #1070 out of 1451 companies in the Consumer Packaged Goods industry, which is below the industry midpoint. Overall, Taiyen Biotech Co has a GF Score™ of 84/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Taiyen Biotech Co's Cyclically Adjusted PS Ratio compare to PG and CL?
According to the Consumer Packaged Goods industry distribution chart, Taiyen Biotech Co ranks #1070 out of 1451 companies for Cyclically Adjusted PS Ratio. This places Taiyen Biotech Co in the lower half of its industry. The industry median Cyclically Adjusted PS Ratio is 0.76. Taiyen Biotech Co's value of 1.67 is 119.7% above this benchmark. Historically, Taiyen Biotech Co's own Cyclically Adjusted PS Ratio has ranged from 1.63 to 2.37 over the past decade. While the company's 10-year median is 1.90 vs. the industry median of 0.76, Taiyen Biotech Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted PS Ratio for a Consumer Packaged Goods company?
The median Cyclically Adjusted PS Ratio among Consumer Packaged Goods companies is 0.76, based on 1,451 companies in the industry. Companies in the top quartile (top 25%) have a Cyclically Adjusted PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cyclically Adjusted PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Taiyen Biotech Co's current Cyclically Adjusted PS Ratio of 1.67 is 119.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted PS Ratio mean?
A high Cyclically Adjusted PS Ratio can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted PS Ratio is the ratio of share price to a company's inflation-adjusted revenue per share over a 10-year period. View historical data on Taiyen Biotech Co and its competitors. For the Consumer Packaged Goods industry, the median Cyclically Adjusted PS Ratio is 0.76 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Taiyen Biotech Co's current Cyclically Adjusted PS Ratio is 1.67, which is 12% below median its own 10-year median of 1.90. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Taiyen Biotech Co stock overvalued right now?
Based on GuruFocus' analysis, Taiyen Biotech Co (TPE:1737) is currently considered Fairly Valued. The stock's GF Value™ is NT$31.83, compared to a current price of NT$32.05 — trading 0.7% above its estimated fair value. The current Cyclically Adjusted PS Ratio is 1.67, which is 12% below median its 10-year median of 1.90 and 119.7% above the Consumer Packaged Goods industry median of 0.76. Taiyen Biotech Co's overall GF Score™ is 84/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted PS Ratio calculated?
Cyclically Adjusted PS Ratio is calculated from a company's financial statements. For Taiyen Biotech Co (TPE:1737), the current Cyclically Adjusted PS Ratio is 1.67 as of Jul. 31, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Taiyen Biotech Co (TPE:1737) Overvalued in 2026?
Based on GuruFocus' analysis, Taiyen Biotech Co stock appears to be overvalued.
The current stock price of NT$32.05 is trading 0.7% above its estimated GF Value™ of NT$31.83.
GuruFocus considers Taiyen Biotech Co to be Fairly Valued.
Key valuation signals for TPE:1737:
Cyclically Adjusted PS Ratio: 1.67 (12% below median its 10-year median of 1.90)
GF Value™: NT$31.83 vs. price of NT$32.05 (0.7% above fair value)
Industry Position: 119.7% above the Consumer Packaged Goods median (#1070 of 1451)
No single metric tells the full story. See the TPE:1737 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Taiyen Biotech Co Ltd operates in personal care and home care products. Its product portfolio comprises beauty care products, health food, skin products, salt products and spices, bottled water, and medical supplies, among others. The group has four reportable segments; Salt products and packaged water department, Biotech cleaning and maintenance department, Construction and services department, and Other departments.. The Salt and Packaged Product Segment accounts for the bulk of revenue. Geographically it operates through the region of Taiwan; however, it also holds a presence in the international market.
84GF Score
Get the complete analysis for TPE:1737
Cyclically Adjusted PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:1737 has been successfully added to your 
